DK627286A - Fremgangsmaade til fremstilling af et metalchelat-protein-konjugat - Google Patents

Fremgangsmaade til fremstilling af et metalchelat-protein-konjugat

Info

Publication number
DK627286A
DK627286A DK627286A DK627286A DK627286A DK 627286 A DK627286 A DK 627286A DK 627286 A DK627286 A DK 627286A DK 627286 A DK627286 A DK 627286A DK 627286 A DK627286 A DK 627286A
Authority
DK
Denmark
Prior art keywords
preparing
protein conjugate
chelat
metal
metal chelat
Prior art date
Application number
DK627286A
Other languages
English (en)
Other versions
DK627286D0 (da
Inventor
Otto A Gansow
Original Assignee
Otto A Gansow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otto A Gansow filed Critical Otto A Gansow
Publication of DK627286D0 publication Critical patent/DK627286D0/da
Publication of DK627286A publication Critical patent/DK627286A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK627286A 1985-04-26 1986-12-23 Fremgangsmaade til fremstilling af et metalchelat-protein-konjugat DK627286A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/727,919 US4824986A (en) 1985-04-26 1985-04-26 Metal chelate protein conjugate
PCT/US1986/000868 WO1986006384A1 (en) 1985-04-26 1986-04-24 Method of forming a metal chelate protein conjugate

Publications (2)

Publication Number Publication Date
DK627286D0 DK627286D0 (da) 1986-12-23
DK627286A true DK627286A (da) 1987-02-26

Family

ID=24924643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK627286A DK627286A (da) 1985-04-26 1986-12-23 Fremgangsmaade til fremstilling af et metalchelat-protein-konjugat

Country Status (10)

Country Link
US (1) US4824986A (da)
EP (3) EP0355860A1 (da)
JP (1) JPS62502618A (da)
KR (1) KR870700639A (da)
CN (1) CN86103488A (da)
AU (2) AU596590B2 (da)
BR (1) BR8606644A (da)
DK (1) DK627286A (da)
ES (1) ES8706965A1 (da)
WO (1) WO1986006384A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227474A (en) * 1987-02-13 1993-07-13 Abbott Laboratories Bifunctional chelating agents
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
PH31170A (en) 1988-10-31 1998-03-20 Dow Chemical Co Chelants possesing ortho ligating functionality and complexes thereof.
WO1990007342A1 (en) * 1988-12-23 1990-07-12 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
DE3922005A1 (de) * 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
DE4136489A1 (de) * 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
US5403862A (en) * 1992-01-17 1995-04-04 University Of Utah Research Foundation Method for oral decorporation of metals
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6740756B1 (en) * 1998-07-07 2004-05-25 Smithkline Beecham Corporation Fluorescent lanthanide chelates
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1427377A4 (en) 2001-09-20 2006-04-12 Cornell Res Foundation Inc METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005084179A2 (en) 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
EP3887033B1 (en) * 2018-11-28 2024-07-24 Cube Biotech GmbH Solid-phase chelator material, method for producing thereof and use thereof for the purification of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
CA1178951A (en) * 1980-03-18 1984-12-04 Claude F. Meares Chelating agents and method
NO169947C (no) * 1981-10-27 1992-08-26 Hybritech Inc Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB2122641B (en) * 1982-06-07 1986-08-06 Otto A Gansow Metal chelate conjugated monoclonal antibodies where in the metal is an emitter
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production

Also Published As

Publication number Publication date
EP0220279A1 (en) 1987-05-06
EP0355860A1 (en) 1990-02-28
US4824986A (en) 1989-04-25
JPS62502618A (ja) 1987-10-08
DK627286D0 (da) 1986-12-23
BR8606644A (pt) 1987-08-04
WO1986006384A1 (en) 1986-11-06
AU596590B2 (en) 1990-05-10
AU5780086A (en) 1986-11-18
CN86103488A (zh) 1987-05-27
EP0315220A1 (en) 1989-05-10
ES554387A0 (es) 1987-07-01
ES8706965A1 (es) 1987-07-01
AU4932490A (en) 1990-06-07
KR870700639A (ko) 1987-12-30

Similar Documents

Publication Publication Date Title
DK627286D0 (da) Fremgangsmaade til fremstilling af et metalchelat-protein-konjugat
DK301986A (da) Fremgangsmaade til fremstilling af 1-hydroxyvitamin-d-forbindelser
DK113088D0 (da) Fremgangsmaade til fremstilling af en thiazepinforbindelse
RO100056A2 (ro) Procedeu de obtinere a metacrilatului de metil
BR8703044A (pt) Metodo para fabricacao de um padrao metalico
DK379985D0 (da) Fremgangsmaade til fremstilling af 6-chlor-n-methyl-2,3,4,5-tetrahydro-lh-benzazepin
ES551064A0 (es) Un metodo para preparar derivados de cefem
DK73186A (da) Fremgangsmaade til fremstilling af et varmeisoleret ledningsroer
ES550467A0 (es) Un metodo para preparar derivados de 9-bencilpurina
DK404686A (da) Fremgangsmaade til fremstilling af salt-stabil karamel
DK161705C (da) Fremgangsmaade til fremstilling af et 13-hydroxy-5-ketomilbemycinderivat
DK193786D0 (da) Fremgangsmaade til fremstilling af n7-amidinosubstituerede mitomycin-c-derivater
DK214385D0 (da) Fremgangsmaade til fremstilling af en valse
DK75487D0 (da) Fremgangsmaade til fremstilling af et butanonderivat
DK75087D0 (da) Fremgangsmaade til fremstilling af et butanonderivat
DK229986D0 (da) Fremgangsmaade til fremstilling af 2-thiocromenylidenethylacetoacetater
DK75287A (da) Fremgangsmaade til fremstilling af et butanonderivat
DK74987D0 (da) Fremgangsmaade til fremstilling af et butanonderivat
DK358686D0 (da) Fremgangsmaade til fremstilling af 5,6-dialkoxyanthranilsyrer
DK18985D0 (da) Fremgangsmaade til fremstilling af et farmakologisk virksomt sulfonylurinstofderivat
DK142387A (da) Fremgangsmaade til fremstilling af et butanonderivat
DK75187D0 (da) Fremgangsmaade til fremstilling af et butanonderivat
DK75387A (da) Fremgangsmaade til fremstilling af et butanonderivat
DK132585D0 (da) Fremgangsmaade til fremstilling af en cephalosporinforbindelse
DK433689D0 (da) Fremgangsmaade til fremstilling af 2-n-propyl-4-amino-5-methoxy-methylpyrimidin

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment